| Name | Title | Contact Details |
|---|---|---|
Jeff Pinto |
CIO and Head of AI | Profile |
Intrigma is a leader in medical scheduling solutions that deliver bottom-line impact to medical groups, hospitals and hospital systems.
Mental Health Centers of Western Illinois is a Pittsfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amanna Health Institute is a Alpena, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AMN Healthcare is the innovator in healthcare workforce solutions and staffing services to healthcare facilities across the nation. AMN Healthcare`s workforce solutions - including managed services programs and recruitment process outsourcing - enable providers to successfully reduce complexity, increase efficiency and improve patient outcomes within the rapidly evolving healthcare environment. The Company provides unparalleled access to the largest network of quality clinicians and physicians through its innovative recruitment strategies and breadth of career opportunities. Clients include acute-care hospitals, government facilities, community health centers and clinics, physician practice groups and many other healthcare settings.
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.